ANI Pharmaceuticals Inc (ANIP) CEO Sells $682,204.50 in Stock

ANI Pharmaceuticals Inc (NASDAQ:ANIP) CEO Arthur Przybyl sold 9,595 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $71.10, for a total value of $682,204.50. Following the sale, the chief executive officer now directly owns 222,994 shares of the company’s stock, valued at $15,854,873.40. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Arthur Przybyl also recently made the following trade(s):

  • On Wednesday, May 15th, Arthur Przybyl sold 30,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.07, for a total value of $2,102,100.00.
  • On Tuesday, March 19th, Arthur Przybyl sold 27,625 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25.

ANIP traded down $0.63 during mid-day trading on Wednesday, reaching $69.14. The stock had a trading volume of 104,701 shares, compared to its average volume of 87,476. The firm has a market capitalization of $836.09 million, a price-to-earnings ratio of 15.00 and a beta of 2.37. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.67 and a current ratio of 0.92. ANI Pharmaceuticals Inc has a 52 week low of $36.92 and a 52 week high of $74.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.25. The firm had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $1.32 EPS. As a group, research analysts forecast that ANI Pharmaceuticals Inc will post 5.97 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Financial Gravity Wealth Inc. bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $54,000. Quantamental Technologies LLC boosted its position in shares of ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 542 shares during the last quarter. South Dakota Investment Council bought a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $45,000. BNP Paribas Arbitrage SA boosted its position in shares of ANI Pharmaceuticals by 55,466.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 1,664 shares during the last quarter. Finally, Truvestments Capital LLC bought a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $140,000. Hedge funds and other institutional investors own 60.02% of the company’s stock.

ANIP has been the topic of a number of recent research reports. ValuEngine upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Raymond James set a $73.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, February 28th. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 19th. Finally, Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price objective on the stock in a research report on Thursday, March 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $84.25.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2019/05/15/ani-pharmaceuticals-inc-anip-ceo-sells-682204-50-in-stock.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: Institutional Investors

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.